Detalles de la búsqueda
1.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Breast Cancer Res Treat
; 193(1): 95-103, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35212906
2.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 189(3): 689-699, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34414532
3.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 191(1): 223-224, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625861
4.
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Breast
; 62: 75-83, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131646
Resultados
1 -
4
de 4
1
Próxima >
>>